C. Ola Landgren, Leader, Translational and Clinical Oncology Program/Experimental Therapeutics at Sylvester Comprehensive Cancer Center, shared on LinkedIn:
“The University of Miami Miller School of Medicine just released ‘Challenging Convention to Accelerate Drug Discovery,’ a new episode of Inside U Miami Medicine. I had the pleasure of joining Dean Henri Ford to talk about the future of multiple myeloma care and how we can bring promising treatments to patients sooner.
Here is the free link to the podcast on Apple Podcasts.
One example we discussed is minimal residual disease (MRD). Years ago, we asked whether measuring how deeply a patient responds to treatment could help us evaluate new myeloma therapies earlier. Patients who participated in clinical trials and investigators who worked together across institutions made it possible to bring that evidence to the FDA. Today, the use of MRD as an endpoint can shorten the path to accelerated approval by years.
We also talked about a principle that guides my work: ‘No patient is average.’ At Sylvester Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami Health System one question I’m especially excited about is how to use what we learn about each patient’s response to guide what comes next. Can we identify who needs more treatment and who can safely spend more time off therapy? These are questions that matter to patients and that deserve the same commitment to excellence we bring to developing new drugs.
Thank you, Dean Henri Ford, for the thoughtful conversation. I hope you’ll give the episode a listen.
Read the University of Miami story here.”
You can also read: European Commission Expands Melphalan Flufenamide Approval to Third-Line Treatment for Multiple Myeloma
